The global Oncolytic Virus Immunotherapy market accrued earnings worth approximately301 (USD Million) in 2020 and is predicted to gain revenue of about 678(USD Million) by 2028, is set to record a CAGR of nearly 12.1% over the period from 2021 to 2028.
The global Oncolytic Virus Immunotherapy market accrued earnings worth approximately301 (USD Million) in 2020 and is predicted to gain revenue of about 678(USD Million) by 2028, is set to record a CAGR of nearly 12.1% over the period from 2021 to 2028. The report offers assessment and analysis of the Oncolytic Virus Immunotherapy market on a global and regional level. The study offers a comprehensive assessment of the market competition, constraints, revenue estimates, opportunities, evolving trends, and industry-validated data. The report provides historical data from 2018 to 2020 along with a forecast from 2021 to 2028 based on revenue (USD Million).
Report Attribute | Details |
---|---|
Base Year | 2020 |
Historic Years | 2016 - 2020 |
Forecast Years | 2021 - 2028 |
Segments Covered | By Product Type, By Application, and By End Use |
Forecast Units | Value (USD Billion), and Volume (Units) |
Quantitative Units | Revenue in USD million/billion and CAGR from 2021 to 2028 |
Regions Covered | North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World |
Countries Covered | U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others |
Number of Companies Covered | 10 companies with scope for including additional 15 companies upon request |
Report Coverage | Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis. |
Customization Scope | Avail customized purchase options to meet your exact research needs. |
Oncolytic virus is a new therapy for treating cancer and it can infect & destroy cancer tissues, thereby acting as in situ cancer vaccine by releasing tumor-specific antigens. Precisely, oncolytic viruses are class of therapeutic agents prompting anti-tumor responses through selectively killing of cell tumors along with inducing of systemic anti-tumor immunization. Reportedly, oncolytic viruses can help in stimulating immune responses of host cells against cancer. Furthermore, oncolytic virus immunotherapy is a novel approach in cancer treatment making use of genetically modified viruses selectively replicating in tumors. Though ability of virus in killing cancer cells has been known long back, clinical trials documenting its therapeutic benefits on cancer patients has been recorded during past decade.
With comprehensive knowledge about viral biology, molecular genetics, and tumor immunology, there has been immense interest in ongoing research activities pertaining to application of oncolytic viruses in treating cancer. For the record, in October 2015, virus referred as T-VEC or talimogene laherparepvec was the first oncolytic virus immunotherapy approved by U.S. FDA for cancer treatment. Furthermore, success of T-VEC has prompted new drug discovery for treating cancer. Additionally, H101- a genetically modified oncolytic adenovirus- used in combination with chemotherapy was approved by Chinese government for treating nasopharyngeal carcinoma in November 2005.
Additionally, oncolytic viruses make use of two mechanisms for treating tumors, namely, selective replicating of viruses within neoplastic cells leading to direct lytic effect on cell tumors and inducting of systemic anti-tumor immunity in human system. Developing of oncolytic viruses as drugs for treating various kinds of cancer is predicted to help market explore new areas of growth in healthcare sector in next few years.
Immunotherapy is a leading treatment in oncology with myriad therapies targeting tumor biology and oncolytic virus immunotherapy being one of the most promising ones. Additionally, the latter provides multimodal approach for effectively targeting & killing malignant tumors. This has resulted in massive use of oncolytic virus immunotherapy in cancer treatment, thereby driving market trends. Apparently, oncolytic virus immunotherapy is tailored for particular cell targets at specific locations and this is projected to have long lasting impact on drug molecule development for cancer treatment. It has been found that oncolytic virus immunotherapy has the ability for inducing potent anti-tumoural effects that help in eliminating cancerous tissues and this has create a massive hype and demand for oncolytic virus immunotherapy in healthcare sector. Moreover, tumor specific oncolytic viruses have proved to be new anticancer agents and its efficacy is being tested intensely in phase I and phase III clinical trials. All these moves and aforementioned factors are projected to be key growth drivers for oncolytic virus immunotherapy market in near future.
Additionally, insights into mechanisms of virus replication, entry, induction, and immune response suppression has resulted into utilization of virus for treating human ailments along with choosing of oncolytic viral vectors for treatment of particular kinds of cancers. This will translate into charting of new growth path for oncolytic virus immunotherapy market in coming decade. Furthermore, oncolytic viruses provide danger signals promoting proficient anti-tumor immune responses in humans. Ability of counteracting cancer mediated immune evasion will steer growth of oncolytic virus immunotherapy industry during forecast timeframe.
The expansion of oncolytic virus immunotherapy market in North America is owing to rise in cases of cancer in North America. Additionally, large-scale presence of giant manufacturers & vendors in the U.S. and Canada will contribute lucratively towards regional market proceeds. Huge government funding of research activities related to novel therapies for cancer treatment & new drug development will proliferate size of oncolytic virus immunotherapy market in North America. Apparently, oncolytic virus immunotherapy industry is likely to experience huge growth prospects in sub-continent due to large proportion of sponsorships from cancer drug molecule manufacturers of the region.
Key players profiled in study include Amgen, Inc., Genelux Corporation, Cold Genesys, Inc., Lokon Pharma AB, Takara Bio, Viralytics Ltd., Shanghai Sunway Biotech, Oncolytics Biotech, Inc., DNAtrix Therapeutics, Transgene sa, Turnstone Biologics, VCN Biosciences, and Vyriad.
By Application
By Product Type
List of Figures
1. Market research Type
2. Market research methodology
3. Global Oncolytic Virus Immunotherapy Market, 2018–2028(USD Million)
4. Porter’s Five Forces Analysis
5. Global Oncolytic Virus Immunotherapy Marketattractiveness, By Application
6. Global Oncolytic Virus Immunotherapy Marketattractiveness, By Product Type
7. Global Oncolytic Virus Immunotherapy Marketshare by Application ,2020 and 2028 (USD Million)
8. Global Oncolytic Virus Immunotherapy Marketby Melanoma, 2018–2028(USD Million)
9. Global Oncolytic Virus Immunotherapy Marketby Myeloma, 2018–2028(USD Million)
10. Global Oncolytic Virus Immunotherapy Marketby Bladder Cancer, 2018–2028(USD Million)
11. Global Oncolytic Virus Immunotherapy Marketby Prostrate Cancer, 2018–2028(USD Million)
12. Global Oncolytic Virus Immunotherapy Marketby Ovarian Cancer, 2018–2028(USD Million)
13. Global Oncolytic Virus Immunotherapy Marketby Breast Cancer, 2018–2028(USD Million)
14. Global Oncolytic Virus Immunotherapy Marketby Lung Cancer, 2018–2028(USD Million)
15. Global Oncolytic Virus Immunotherapy Marketshare by Product Type ,2020 and 2028 (USD Million)
16. Global Oncolytic Virus Immunotherapy Marketby HSV-based Oncolytic Viruses, 2018–2028(USD Million)
17. Global Oncolytic Virus Immunotherapy Marketby Vaccinia Virus-based Oncolytic Viruses, 2018–2028(USD Million)
18. Global Oncolytic Virus Immunotherapy Marketby Vesicular Stomatitis Virus-based Oncolytic Viruses, 2018–2028(USD Million)
19. Global Oncolytic Virus Immunotherapy Marketby Newcastle Disease Virus-based Oncolytic Viruses, 2018–2028(USD Million)
20. Global Oncolytic Virus Immunotherapy Marketby Adenovirus-based Oncolytic Viruses, 2018–2028(USD Million)
21. Global Oncolytic Virus Immunotherapy Marketshare, by Region, 2020 and 2028
22. North America Oncolytic Virus Immunotherapy Market, 2018–2028(USD Million)
23. Europe Oncolytic Virus Immunotherapy Market, 2018–2028(USD Million)
24. Asia Pacific Oncolytic Virus Immunotherapy Market, 2018–2028(USD Million)
25. Latin America Oncolytic Virus Immunotherapy Market, 2018–2028(USD Million)
26. The Middle East and Africa Oncolytic Virus Immunotherapy Market, 2018–2028(USD Million)
List of Tables
1. Global Oncolytic Virus Immunotherapy Market: snapshot
2. Drivers of the Oncolytic Virus Immunotherapy Market: impact analysis
3. North America Oncolytic Virus Immunotherapy Market revenue, By Application ,2018–2028(USD Million)
4. North America Oncolytic Virus Immunotherapy Market revenue, By Product Type ,2018–2028(USD Million)
5. The U.S. Oncolytic Virus Immunotherapy Market revenue, By Application ,2018–2028(USD Million)
6. The U.S. Oncolytic Virus Immunotherapy Market revenue, By Product Type ,2018–2028(USD Million)
7. Rest of North America Oncolytic Virus Immunotherapy Market revenue, By Application ,2018–2028(USD Million)
8. Rest of North America Oncolytic Virus Immunotherapy Market revenue, By Product Type ,2018–2028(USD Million)
9. Europe Oncolytic Virus Immunotherapy Market revenue, By Application ,2018–2028(USD Million)
10. Europe Oncolytic Virus Immunotherapy Market revenue, By Product Type ,2018–2028(USD Million)
11. UK Oncolytic Virus Immunotherapy Market revenue, By Application ,2018–2028(USD Million)
12. UK Oncolytic Virus Immunotherapy Market revenue, By Product Type ,2018–2028(USD Million)
13. France Oncolytic Virus Immunotherapy Market revenue, By Application ,2018–2028(USD Million)
14. France Oncolytic Virus Immunotherapy Market revenue, By Product Type ,2018–2028(USD Million)
15. Germany Oncolytic Virus Immunotherapy Market revenue, By Application ,2018–2028(USD Million)
16. Germany Oncolytic Virus Immunotherapy Market revenue, By Product Type ,2018–2028(USD Million)
17. Rest of Europe Oncolytic Virus Immunotherapy Market revenue, By Application ,2018–2028(USD Million)
18. Rest of Europe Oncolytic Virus Immunotherapy Market revenue, By Product Type ,2018–2028(USD Million)
19. Asia Pacific Oncolytic Virus Immunotherapy Market revenue, By Application ,2018–2028(USD Million)
20. Asia Pacific Oncolytic Virus Immunotherapy Market revenue, By Product Type ,2018–2028(USD Million)
21. China Oncolytic Virus Immunotherapy Market revenue, By Application ,2018–2028(USD Million)
22. China Oncolytic Virus Immunotherapy Market revenue, By Product Type ,2018–2028(USD Million)
23. Japan Oncolytic Virus Immunotherapy Market revenue, By Application ,2018–2028(USD Million)
24. Japan Oncolytic Virus Immunotherapy Market revenue, By Product Type ,2018–2028(USD Million)
25. India Oncolytic Virus Immunotherapy Market revenue, By Application ,2018–2028(USD Million)
26. India Oncolytic Virus Immunotherapy Market revenue, By Product Type ,2018–2028(USD Million)
27. Rest of Asia Pacific Oncolytic Virus Immunotherapy Market revenue, By Application ,2018–2028(USD Million)
28. Rest of Asia Pacific Oncolytic Virus Immunotherapy Market revenue, By Product Type ,2018–2028(USD Million)
29. Latin America Oncolytic Virus Immunotherapy Market revenue, By Application ,2018–2028(USD Million)
30. Latin America Oncolytic Virus Immunotherapy Market revenue, By Product Type ,2018–2028(USD Million)
31. Brazil Oncolytic Virus Immunotherapy Market revenue, By Application ,2018–2028(USD Million)
32. Brazil Oncolytic Virus Immunotherapy Market revenue, By Product Type ,2018–2028(USD Million)
33. Rest of Latin America Oncolytic Virus Immunotherapy Market revenue, By Application ,2018–2028(USD Million)
34. Rest of Latin America Oncolytic Virus Immunotherapy Market revenue, By Product Type ,2018–2028(USD Million)
35. The Middle East and Africa Oncolytic Virus Immunotherapy Market revenue, By Application ,2018–2028(USD Million)
36. The Middle East and Africa Oncolytic Virus Immunotherapy Market revenue, By Product Type ,2018–2028(USD Million)
37. Saudi Arabia Oncolytic Virus Immunotherapy Market revenue, By Application ,2018–2028(USD Million)
38. Saudi Arabia Oncolytic Virus Immunotherapy Market revenue, By Product Type ,2018–2028(USD Million)
39. South Africa Oncolytic Virus Immunotherapy Market revenue, By Application ,2018–2028(USD Million)
40. South Africa Oncolytic Virus Immunotherapy Market revenue, By Product Type ,2018–2028(USD Million)
41. Rest of the Middle East & Africa Oncolytic Virus Immunotherapy Market revenue, By Application ,2018–2028(USD Million)
42. Rest of the Middle East & Africa Oncolytic Virus Immunotherapy Market revenue, By Product Type ,2018–2028(USD Million)
Immunotherapy is a leading treatment in oncology with myriad therapies targeting tumor biology and oncolytic virus immunotherapy being one of the most promising ones. Additionally, the latter provides multimodal approach for effectively targeting & killing malignant tumors. This has resulted in massive use of oncolytic virus immunotherapy in cancer treatment, thereby driving market trends. Apparently, oncolytic virus immunotherapy is tailored for particular cell targets at specific locations and this is projected to have long lasting impact on drug molecule development for cancer treatment. It has been found that oncolytic virus immunotherapy has the ability for inducing potent anti-tumoural effects that help in eliminating cancerous tissues and this has create a massive hype and demand for oncolytic virus immunotherapy in healthcare sector. Moreover, tumor specific oncolytic viruses have proved to be new anticancer agents and its efficacy is being tested intensely in phase I and phase III clinical trials. All these moves and aforementioned factors are projected to be key growth drivers for oncolytic virus immunotherapy market in near future.
Additionally, insights into mechanisms of virus replication, entry, induction, and immune response suppression has resulted into utilization of virus for treating human ailments along with choosing of oncolytic viral vectors for treatment of particular kinds of cancers. This will translate into charting of new growth path for oncolytic virus immunotherapy market in coming decade.
According to Zion market research report, the global Oncolytic Virus Immunotherapy market accrued earnings worth approximately301 (USD Million) in 2020 and is predicted to gain revenue of about 678(USD Million) by 2028, is set to record a CAGR of nearly 12.1% over the period from 2021 to 2028.
North America will contribute lucratively towards the global market size over the estimated timeline. The regional market surge is due to rise in cases of cancer in North America. Additionally, large-scale presence of giant manufacturers & vendors in the U.S. and Canada will contribute lucratively towards regional market proceeds. Huge government funding of research activities related to novel therapies for cancer treatment & new drug development will proliferate size of oncolytic virus immunotherapy market in North America. Apparently, oncolytic virus immunotherapy industry is likely to experience huge growth prospects in sub-continent due to large proportion of sponsorships from cancer drug molecule manufacturers of the region.
The key market participants include Amgen, Inc., Genelux Corporation, Cold Genesys, Inc., Lokon Pharma AB, Takara Bio, Viralytics Ltd., Shanghai Sunway Biotech, Oncolytics Biotech, Inc., DNAtrix Therapeutics, Transgene sa, Turnstone Biologics, VCN Biosciences, and Vyriad.
Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008
US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed